Aditxt, Inc., a biotechnology company, has communicated with the U.S. Securities and Exchange Commission (SEC) regarding its Preliminary Proxy Statement on Schedule 14A. The SEC had previously commented on the company's response to a comment letter, highlighting concerns about the Exchange Agreements related to the merger with Evofem Biosciences, Inc. not being separate from the Merger Agreement. The SEC's correspondence referenced a Form 8-K filed by Evofem Biosciences on December 27, 2023, and a section of the Merger Agreement filed on December 12, 2023. In response, Aditxt has removed Proposal No. 3 from its revised Preliminary Proxy Statement and stated that it will include the required disclosures when the proposal is submitted to stockholders at a future date. The company's legal counsel, Sean F. Reid from Sheppard, Mullin, Richter & Hampton LLP, is the point of contact for further inquiries.

Aditxt, Inc., a biotechnology company, has communicated with the U.S. Securities and Exchange Commission (SEC) regarding its Preliminary Proxy Statement on Schedule 14A. The SEC had previously commented on the company's response to a comment letter, highlighting concerns about the Exchange Agreements related to the merger with Evofem Biosciences, Inc. not being separate from the Merger Agreement. The SEC's correspondence referenced a Form 8-K filed by Evofem Biosciences on December 27, 2023, and a section of the Merger Agreement filed on December 12, 2023. In response, Aditxt has removed Proposal No. 3 from its revised Preliminary Proxy Statement and stated that it will include the required disclosures when the proposal is submitted to stockholders at a future date. The company's legal counsel, Sean F. Reid from Sheppard, Mullin, Richter & Hampton LLP, is the point of contact for further inquiries.